We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » 21st Century Cures Passes House Panel 51-0, Moves on to House Floor

21st Century Cures Passes House Panel 51-0, Moves on to House Floor

May 22, 2015

The House Energy & Commerce Committee voted resoundingly to approve the 21st Century Cures Act, sending the measure — which includes a provision to ease U.S. device trials by allowing a single central review board to monitor multiple trial sites — to the House floor for consideration.

Currently, device trials must be cleared by a local institutional review board at each research site, a requirement AdvaMed calls unnecessary and redundant. JC Scott, head of government affairs at the trade group, says the FDA is aware of the problem but lacks the power to change the policy.

In another change, the FDA overhaul package would simplify informed consent rules around device trials that pose no more than minimal risk to the patient, as long as they include appropriate safeguards.

In addition to clinical trial reforms, H.R. 6 would allow devicemakers developing so-called breakthrough technologies to ask the FDA for a priority review designation before submitting an application.

The bill also clarifies and expands the definition of “valid scientific evidence” in the context of device applications, ensuring that manufacturers can submit peer-reviewed journal studies, results from overseas trials and registry data.

Further, the bill would expand the humanitarian device exemption program to cover devices treating conditions affecting up to 8,000 people in the U.S., double the current definition.

Rules around medical device software would also be updated, limiting the FDA’s authority to regulate products that don’t pose a risk to patient health. Finally, the law would allow devicemakers to use third-party inspectors more broadly (IDDM, May 15).

The legislation includes an amendment from Reps. Anna Eshoo (D-Calif.) and Leonard Lance (R-N.J.) that would exempt FDA user fees from sequestration – a provision Eschoo said would ensure that private dollars are not locked up.

Scott praised the user fee amendment, but expressed reservations about a provision in the bill’s offset package that would apply Medicare payments for durable medical equipment to Medicaid patients as of 2020.

Industry has had concerns over low rates set through Medicare competitive bidding and there hasn’t been a good analysis done of possible patient access issues, he says.

Committee chairman Fred Upton (R-Mich.) hinted that more amendments might be added before the bill hits the House floor for approval. Scott declined to speculate on the chances of equivalent legislation in the Senate, where the issues are being researched.

View the bill at www.fdanews.com/05-20-15-21CCbill.pdf. — Lena Freund and Elizabeth Orr

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing